Related Experiment Video
Updated: May 28, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
The prostate-specific antigen screening conundrum: examining the evidence
1Wake ForestUniversity School of Medicine, Winston-Salem, NC, USA. moeorourke@gmail.com
Seminars in Oncology Nursing
|October 25, 2011
Summary
Prostate-specific antigen (PSA) screening has limited evidence for widespread use in asymptomatic men. Evidence supports its use in moderate- to high-risk groups, but not for those with short life expectancies.
Area of Science:
- Urology
- Oncology
- Evidence-Based Medicine
Background:
- Prostate-specific antigen (PSA) screening is a widely discussed topic in men's health.
- Guidelines and recommendations for PSA screening vary, necessitating a review of the supporting evidence.
Purpose of the Study:
- To review current guidelines and recommendations for prostate-specific antigen (PSA) screening.
- To evaluate the state of scientific evidence supporting PSA screening.
Main Methods:
- Literature search of nursing and medical journals.
- Inclusion of published guidelines and Cochrane Systematic Reviews.
Main Results:
- Limited evidence supports widespread PSA screening in asymptomatic men.
- Some evidence supports PSA screening for men in moderate- to high-risk categories.
- No evidence supports PSA screening for men with life expectancies under 10 years.
Conclusions:
- The evidence base for broad PSA screening is weak.
- Guidelines on PSA screening are not uniform.
- Nurses play a crucial role in educating patients on the evidence and facilitating informed decision-making regarding PSA screening.
